NexGel (NXGL) vs Regentis Biomaterials (RGNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Regentis Biomaterials is the larger company by market cap ($11.2 million vs $97,622), about 115.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NXGL | RGNT |
|---|---|---|
| Share price | $0.2003 | $1.60 |
| Market cap | $97.62K | $11.24M |
| 1-day change | +33.53% | -5.88% |
| YTD return | — | -76.26% |
| EPS (TTM) | $-19.83 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $57.00 | $15.50 |
| 52-week low | $0.151 | $1.23 |
| Distance from 52-week high | -99.65% | -89.68% |
| Analyst consensus | hold | none |
| Avg. price target upside | — | +525.00% |
| Average volume | 37.86K | 76.68K |
| Shares outstanding | 487.38K | 7.02M |
| Employees | 19 | — |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regentis Biomaterials is about 115.1 times larger than NexGel by market value ($11.24M vs $97.62K).
About NexGel
NXGL stock →NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
Health Care · Medical/Dental Instruments · 19 employees
About Regentis Biomaterials
RGNT stock →Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Health Care · Industrial Specialties
NXGL vs RGNT FAQ
Which is bigger, NexGel or Regentis Biomaterials?
Regentis Biomaterials (RGNT) is larger, with a market capitalization of $11.24M compared with $97.62K for NexGel (NXGL).
Are NexGel and Regentis Biomaterials in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for NexGel and Industrial Specialties for Regentis Biomaterials.